Incyte treatment for advanced anal cancer approved in Europe
EC decision introduces first systemic option for adults with advanced SCAC
Read More
Author: John Pinching
Dr Michelle Morrow
Nucleome has appointed Dr Michelle Morrow as CSO
Read More
Dr Klaas Zuideveld
TECregen has appointed Dr Klaas Zuideveld as CEO
Read More
HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
First‑in‑human phase 1/2a study launches in China and the US targeting advanced cancers
Read More
Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
New funding will support the phase 2 expansion trial of THEO-260
Read More- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
